A detailed history of Hilltop Holdings Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hilltop Holdings Inc. holds 3,143 shares of VRTX stock, worth $1.42 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
3,143
Previous 684 359.5%
Holding current value
$1.42 Million
Previous $320,000 356.56%
% of portfolio
0.1%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $1.13 Million - $1.24 Million
2,459 Added 359.5%
3,143 $1.46 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $815 - $892
2 Added 0.29%
684 $285,000
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $3,430 - $4,106
-10 Reduced 1.45%
682 $277,000
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $3,719 - $3,987
-11 Reduced 1.56%
692 $240,000
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $2,200 - $2,463
-7 Reduced 0.99%
703 $247,000
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $566 - $646
-2 Reduced 0.28%
710 $223,000
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $194,966 - $217,537
712 New
712 $206,000
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $282,922 - $333,639
-1,509 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $312,393 - $364,136
1,509 New
1,509 $324,000
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $193,527 - $229,446
-757 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $170,688 - $223,920
757 New
757 $220,000
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $233,029 - $294,850
-1,534 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $257,297 - $295,663
1,534 New
1,534 $296,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hilltop Holdings Inc. Portfolio

Follow Hilltop Holdings Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hilltop Holdings Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hilltop Holdings Inc. with notifications on news.